



Proteomics International

LABORATORIES LTD

ASX/Media Release

9 February 2016

ASX code: PIQ

New Company Website and Corporate Video

Life sciences company Proteomics International Laboratories Ltd (ASX: PIQ) (the Company, PILL) is pleased to announce the launch of its new company website.

The website is available at: www.proteomics.com.au or www.proteomicsinternational.com

The new website replaces the previous business and corporate websites in one comprehensive site designed to provide details of the company's full range of services plus information for investors.

PILL is also pleased to present its new corporate video, which describes the Company's groundbreaking predictive test for diabetic kidney disease. **The video is accessible via the PromarkerD page on the website.**

ENDS

For further information please contact:

Dr Richard Lipscombe	Media and Investor Inquiries
Managing Director	James Moses
Proteomics International Laboratories Ltd	Director (Head of Business Relations)
T: +61 8 9389 1992	T: +61 420 991 574
E: enquiries@proteomicsinternational.com	E: j.moses@proteomicsinternational.com
www.proteomicsinternational.com	

Greg Wood [Financial Advisor]
Managing Director
K S Capital
T: +61 416 076 377
E: g.wood@kscapital.com.au

About Proteomics International Laboratories (PILL)

PILL is an ASX listed (ASX: PIQ) life science company focused on the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics is an integral part of the biotechnology and life sciences industries and plays a key role in understanding disease and biological systems.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA, 6009 Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

PILL is recognised as a global leader in its field. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia. The Company's business model uses its proprietary technology platform which operates across three synergistic proteomics-based business units in massive growth markets:

- 1. Diagnostics:** Biomarkers of diseases and personalised medicine - focus on diabetic kidney disease and Alzheimer's disease. The biomarkers market is estimated to double in size to \$45.6 billion by 2020.
- 2. Analytical services:** Specialist contract research, analytical testing and consultancy - fee for service model. The specialist proteomics market alone represents a massive global market estimated to be worth \$20.8 billion by 2018.
- 3. Drug discovery:** Therapeutic drug discovery with a focus on painkillers and antibiotics. The peptide therapeutics market is currently estimated to be worth \$17 billion.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA, 6009 Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com